Inclusion Criteria:

          -  At least one measurable (Parts 1-4) or non-measurable lesion (Parts 1-3), not
             previously irradiated, as defined by RECIST 1.1

          -  ECOG Performance Status 0 or 1, 2 with approval

          -  Adequate Bone Marrow Function

          -  Adequate Renal Function

          -  Adequate Liver Function

          -  Resolved acute effects of any prior therapy

          -  Able to provide adequate archival tumor tissue or freshly obtained tumor tissue (some
             participants will require mandatory pre- and on-treatment biopsy is part of the
             biomarker cohort).

          -  Life expectancy of at least 3 months.

          -  Part 1 and Part 2: Participants who are intolerant or resistant to standard treatment
             for selected solid tumors.

          -  Part 3: Participants with advanced/metastatic RCC with a clear cell component and
             progressed with no standard therapy available.

          -  Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and
             progressed on at least 1 prior therapy.

          -  Part 4, Cohort 2: Participants with MSS CRC with intermediate TMB and progressed with
             no satisfactory alternative treatment available, but has not received prior treatment
             with an anti-PD-(L)1 therapy.

          -  Part 4, Cohort 3: Participants with metastatic gastric or GEJ adenocarcinoma that is
             PD-L1 positive that has progressed on at least 2 but no more than 3 prior chemotherapy
             regiments, but has not received prior treatment with an anti-PD-(L)1 therapy.

          -  Part 4, Cohort 4: Participants with metastatic RCC with a clear cell component with
             IMDC intermediate or poor risk that have not received any prior systemic therapy for
             metastatic disease.

        Exclusion Criteria:

          -  Known active uncontrolled or symptomatic CNS metastases.

          -  Any other active malignancy within 2 years prior to enrollment.

          -  Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer
             therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies
             or investigational drug(s) taken on another study) prior to study entry.

          -  Active or history of autoimmune disease requiring >10mg/day prednisone or other
             concurrent immunosuppressive therapy.

          -  Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as
             defined in protocol.

          -  Retinal or other serious ophthalmic disorders as defined in protocol.

          -  Clinically significant cardiac disease as defined in protocol.

          -  Uncontrolled HTN that cannot be controlled by medications.

          -  Inability to consume or absorb study drug.

          -  Known or suspected hypersensitivity to PF-07265807.

          -  Prohibited concomitant medications as defined in protocol.

          -  Active inflammatory GI disease, uncontrollable chronic diarrhea, or previous gastric
             resection or lap band surgery affecting absorption.

          -  Active bleeding disorder.

        For Part 2, Part 3, and Part 4, Cohorts 2-4:

          -  Known history of non-infectious pneumonitis that required steroid treatment or current
             pneumonitis.

          -  Discontinuation of prior checkpoint inhibitor for treatment-related toxicity.

          -  Experienced >= G3 treatment-related irAE with prior PD-(L)1 agent.